CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Deciphera Pharma - DCPH CFD

    14.75
    1.8%
    0.09
    Low: 14.75
    High: 15.39
    Market Trading Hours* (UTC) Opens on Monday at 14:30

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.09
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Deciphera Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 15.02
    Open* 14.85
    1-Year Change* -1.72%
    Day's Range* 14.75 - 15.39
    52 wk Range 9.90-22.76
    Average Volume (10 days) 590.38K
    Average Volume (3 months) 13.96M
    Market Cap 968.69M
    P/E Ratio -100.00K
    Shares Outstanding 80.12M
    Revenue 151.41M
    EPS -2.35
    Dividend (Yield %) N/A
    Beta 0.48
    Next Earnings Date Feb 5, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 14.75 -0.19 -1.27% 14.94 15.40 14.74
    Dec 7, 2023 15.02 1.69 12.68% 13.33 15.49 13.33
    Dec 6, 2023 13.45 0.62 4.83% 12.83 13.72 12.83
    Dec 5, 2023 13.27 0.10 0.76% 13.17 13.40 12.65
    Dec 4, 2023 13.30 0.58 4.56% 12.72 13.39 12.72
    Dec 1, 2023 12.89 0.39 3.12% 12.50 12.89 12.36
    Nov 30, 2023 12.59 0.22 1.78% 12.37 12.86 12.37
    Nov 29, 2023 12.35 0.26 2.15% 12.09 12.76 12.00
    Nov 28, 2023 12.16 0.20 1.67% 11.96 12.19 11.89
    Nov 27, 2023 12.08 0.31 2.63% 11.77 12.11 11.77
    Nov 24, 2023 12.12 0.39 3.32% 11.73 12.30 11.73
    Nov 22, 2023 12.09 0.05 0.42% 12.04 12.31 11.99
    Nov 21, 2023 12.06 -0.01 -0.08% 12.07 12.25 11.98
    Nov 20, 2023 12.31 0.49 4.15% 11.82 12.60 11.76
    Nov 17, 2023 12.12 0.11 0.92% 12.01 12.34 11.97
    Nov 16, 2023 12.21 -0.03 -0.25% 12.24 12.24 11.77
    Nov 15, 2023 12.30 0.19 1.57% 12.11 12.72 12.11
    Nov 14, 2023 12.30 0.62 5.31% 11.68 12.45 11.68
    Nov 13, 2023 11.60 0.33 2.93% 11.27 11.65 11.12
    Nov 10, 2023 11.47 0.14 1.24% 11.33 11.55 11.04

    Deciphera Pharma Events

    Time (UTC) Country Event
    Monday, February 5, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Deciphera Pharmaceuticals Inc Earnings Release
    Q4 2023 Deciphera Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 134.036 96.148 42.087 25 0
    Revenue 134.036 96.148 42.087 25 0
    Total Operating Expense 316.758 396.225 313.277 225.726 104.099
    Selling/General/Admin. Expenses, Total 120.167 136.253 114.082 68.116 21.212
    Research & Development 187.821 257.04 198.97 157.61 82.887
    Operating Income -182.722 -300.077 -271.19 -200.726 -104.099
    Interest Income (Expense), Net Non-Operating 4.513 0.113 4.701 8.47 4.245
    Net Income Before Taxes -178.209 -299.964 -266.489 -192.256 -99.854
    Net Income After Taxes -178.931 -299.964 -266.489 -192.256 -99.854
    Net Income Before Extra. Items -178.931 -299.964 -266.489 -192.256 -99.854
    Net Income -178.931 -299.964 -266.489 -192.256 -99.854
    Income Available to Common Excl. Extra. Items -178.931 -299.964 -266.489 -192.256 -99.854
    Income Available to Common Incl. Extra. Items -178.931 -299.964 -266.489 -192.256 -99.854
    Diluted Net Income -178.931 -299.964 -266.489 -192.256 -99.854
    Diluted Weighted Average Shares 75.5002 58.0843 55.781 42.8691 35.3905
    Diluted EPS Excluding Extraordinary Items -2.36994 -5.16428 -4.77742 -4.48473 -2.82149
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -2.36994 -5.16428 -4.77742 -4.48473 -2.82149
    Total Extraordinary Items
    Cost of Revenue, Total 8.77 2.932 0.225
    Gross Profit 125.266 93.216 41.862
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 38.304 33.445 36.345 35.974 32.494
    Revenue 38.304 33.445 36.345 35.974 32.494
    Cost of Revenue, Total 0.173 0.488 3.245 3.344 1.799
    Gross Profit 38.131 32.957 33.1 32.63 30.695
    Total Operating Expense 91.079 86.702 83.506 80.855 76.282
    Selling/General/Admin. Expenses, Total 32.61 31.449 32.195 30.026 29.625
    Research & Development 58.296 54.765 48.066 47.485 44.858
    Operating Income -52.775 -53.257 -47.161 -44.881 -43.788
    Interest Income (Expense), Net Non-Operating 4.213 3.648 1.948 1.838 0.727
    Net Income Before Taxes -48.562 -49.609 -45.213 -43.043 -43.061
    Net Income After Taxes -48.562 -49.609 -45.935 -43.043 -43.061
    Net Income Before Extra. Items -48.562 -49.609 -45.935 -43.043 -43.061
    Net Income -48.562 -49.609 -45.935 -43.043 -43.061
    Income Available to Common Excl. Extra. Items -48.562 -49.609 -45.935 -43.043 -43.061
    Income Available to Common Incl. Extra. Items -48.562 -49.609 -45.935 -43.043 -43.061
    Diluted Net Income -48.562 -49.609 -45.935 -43.043 -43.061
    Diluted Weighted Average Shares 85.0203 82.6766 76.4408 78.2066 72.1334
    Diluted EPS Excluding Extraordinary Items -0.57118 -0.60004 -0.60092 -0.55038 -0.59696
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.57118 -0.60004 -0.60092 -0.55038 -0.59696
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 392.958 339.014 584.031 593.408 301.037
    Cash and Short Term Investments 324.486 285.634 551.93 579.576 293.764
    Cash & Equivalents 64.741 87.063 105.897 120.32 293.764
    Prepaid Expenses 25.482 18.66 12.489 13.832 7.273
    Total Assets 454.039 429.484 642.432 622.409 315.559
    Property/Plant/Equipment, Total - Net 43.254 45.41 45.924 27.491 13.453
    Property/Plant/Equipment, Total - Gross 53.338 52.546 50.046 29.321 14.67
    Accumulated Depreciation, Total -10.084 -7.136 -4.122 -1.83 -1.217
    Other Long Term Assets, Total 3.277 3.11 3.102 1.51 1.069
    Total Current Liabilities 86.469 96.773 69.992 60.038 22.743
    Accounts Payable 18.612 13.13 12.308 19.575 8.308
    Accrued Expenses 50.608 54.131 54.303 40.463 14.248
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 0.187
    Total Liabilities 112.348 124.764 98.756 75.942 35.578
    Total Long Term Debt 0 0 0 0 1.107
    Long Term Debt 0 1.107
    Other Liabilities, Total 25.879 27.991 28.764 15.904 11.728
    Total Equity 341.691 304.72 543.676 546.467 279.981
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Additional Paid-In Capital 1575.36 1358.52 1297.56 1033.82 575.327
    Retained Earnings (Accumulated Deficit) -1233.36 -1054.43 -754.468 -487.979 -295.723
    Total Liabilities & Shareholders’ Equity 454.039 429.484 642.432 622.409 315.559
    Total Common Shares Outstanding 67.6374 58.5496 57.5961 51.6176 37.6768
    Common Stock 0.676 0.585 0.576 0.516 0.377
    Short Term Investments 259.745 198.571 446.033 459.256
    Unrealized Gain (Loss) -0.1 0.111
    Total Receivables, Net 22.429 20.595 13.896
    Accounts Receivable - Trade, Net 22.429 20.595 13.896
    Total Inventory 20.561 14.125 5.716
    Long Term Investments 14.55 41.95 9.375
    Other Current Liabilities, Total 17.249 29.512 3.381
    Other Equity, Total -0.983 0.051 0.111
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 417.576 405.05 476.159 392.958 420.879
    Cash and Short Term Investments 339.075 328.74 398.633 324.486 364.577
    Cash & Equivalents 108.087 81.394 114.637 64.741 82.538
    Short Term Investments 230.988 247.346 283.996 259.745 282.039
    Total Receivables, Net 27.549 23.2 22.439 22.429 23.278
    Accounts Receivable - Trade, Net 27.549 23.2 22.439 22.429 23.278
    Total Inventory 27.105 25.343 25.528 20.561 19.129
    Prepaid Expenses 23.847 27.767 29.559 25.482 13.895
    Total Assets 497.836 509.618 549.019 454.039 475.952
    Property/Plant/Equipment, Total - Net 39.073 40.546 41.956 43.254 44.791
    Long Term Investments 37.85 60.683 27.627 14.55 7.006
    Other Long Term Assets, Total 3.337 3.339 3.277 3.277 3.276
    Total Current Liabilities 92.894 81.034 83.913 86.469 75.468
    Accounts Payable 21.453 18.211 19.67 18.612 12.8
    Accrued Expenses 45.56 39.447 43.521 50.608 50.179
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 25.881 23.376 20.722 17.249 12.489
    Total Liabilities 116.166 105.188 108.935 112.348 102.176
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 23.272 24.154 25.022 25.879 26.708
    Total Equity 381.67 404.43 440.084 341.691 373.776
    Common Stock 0.799 0.788 0.785 0.676 0.674
    Additional Paid-In Capital 1762.88 1736.14 1722.45 1575.36 1562.57
    Retained Earnings (Accumulated Deficit) -1381.11 -1331.53 -1282.97 -1233.36 -1187.43
    Other Equity, Total -0.896 -0.967 -0.181 -0.983 -2.042
    Total Liabilities & Shareholders’ Equity 497.836 509.618 549.019 454.039 475.952
    Total Common Shares Outstanding 79.9756 78.7729 78.5078 67.6374 67.4297
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -178.931 -299.964 -266.489 -192.256 -99.854
    Cash From Operating Activities -152.862 -240.824 -239.683 -149.296 -86.783
    Cash From Operating Activities 2.946 3.014 2.305 0.83 0.317
    Non-Cash Items 54.771 55.306 38.353 17.369 9.688
    Cash Interest Paid 0 0 0.067 0.084
    Changes in Working Capital -32.37 0.82 -13.852 24.761 3.066
    Cash From Investing Activities -34.309 176.848 28.459 -460.522 -2.194
    Capital Expenditures -0.841 -5.97 -5.316 -4.935 -1.125
    Cash From Financing Activities 164.994 14.89 226.801 436.374 185.987
    Financing Cash Flow Items -0.425 -0.04 -0.815 -0.62 -0.674
    Issuance (Retirement) of Stock, Net 165.419 14.93 227.616 438.288 186.848
    Issuance (Retirement) of Debt, Net 0 0 -1.294 -0.187
    Net Change in Cash -22.322 -48.834 15.577 -173.444 97.01
    Other Investing Cash Flow Items, Total -33.468 182.818 33.775 -455.587 -1.069
    Foreign Exchange Effects -0.145 0.252
    Deferred Taxes 0.722
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -49.609 -178.931 -132.996 -89.953 -46.892
    Cash From Operating Activities -49.455 -152.862 -117.704 -96.876 -51.352
    Cash From Operating Activities 0.608 2.946 2.345 1.603 0.783
    Non-Cash Items 12.05 54.771 42.274 29.432 15.477
    Changes in Working Capital -12.504 -32.37 -29.327 -37.958 -20.72
    Cash From Investing Activities -35.414 -34.309 -50.613 -44.542 59.652
    Capital Expenditures -0.36 -0.841 -0.86 -0.287 0
    Other Investing Cash Flow Items, Total -35.054 -33.468 -49.753 -44.255 59.652
    Cash From Financing Activities 134.686 164.994 164.516 164.307 0.083
    Financing Cash Flow Items -0.634 -0.425 -0.425 -0.425
    Issuance (Retirement) of Stock, Net 135.32 165.419 164.941 164.732 0.083
    Foreign Exchange Effects 0.079 -0.145 -0.724 -0.254 -0.114
    Net Change in Cash 49.896 -22.322 -4.525 22.635 8.269
    Cash Interest Paid
    Issuance (Retirement) of Debt, Net
    Deferred Taxes 0.722
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Brightstar Associates LLC Corporation 28.0961 22145707 2427693 2023-02-28 LOW
    Deerfield Management Company, L.P. Hedge Fund 8.5092 6707026 1488388 2023-06-30 MED
    Redmile Group, LLC Investment Advisor/Hedge Fund 6.1894 4878566 -703539 2023-06-30 LOW
    Armistice Capital LLC Hedge Fund 5.7852 4560000 460000 2023-06-30 MED
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.5563 4379537 -218820 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 5.3982 4254953 50073 2023-06-30 LOW
    Braidwell LP Hedge Fund 4.6262 3646419 405068 2023-06-30 HIGH
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.0211 3169495 -152655 2023-06-30 LOW
    Polar Capital LLP Investment Advisor/Hedge Fund 2.2202 1750000 0 2023-06-30 LOW
    Goldman Sachs & Company, Inc. Research Firm 2.0342 1603391 -1112760 2023-06-30 MED
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.787 1408514 36718 2023-06-30 LOW
    Nuveen LLC Pension Fund 1.7185 1354565 33549 2023-06-30 LOW
    New Leaf Venture Partners LLC Venture Capital 1.5346 1209571 0 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.4075 1109405 43301 2023-06-30 LOW
    Morgan Stanley & Co. LLC Research Firm 1.1415 899748 544847 2023-06-30 MED
    Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 1.1129 877172 -22507 2023-06-30 MED
    Assenagon Asset Management S.A. Investment Advisor 1.0767 848632 0 2023-06-30 HIGH
    BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.8511 670882 -126584 2023-06-30 LOW
    Point72 Asset Management, L.P. Hedge Fund 0.7853 618946 544995 2023-06-30 HIGH
    Parkman Healthcare Partners LLC Hedge Fund 0.7273 573239 81467 2023-06-30

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Deciphera Pharma Company profile

    About Deciphera Pharmaceuticals Inc

    Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. The Company has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a broad portfolio of medicines. The Company has one approved drug, QINLOCK, which is a switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition, the Company is developing three clinical-stage drug candidates, which includes Vimseltinib (DCC-3014) - colony stimulating factor 1 receptor (CSF1R) Kinase Inhibition for Tenosynovial Giant Cell Tumor (TGCT), Rebastinib - TEK tyrosine kinase (TIE2) Kinase Inhibition for advanced or Metastatic Solid Tumors, and DCC-3116 - ULK Kinase Inhibition for Mutant RAS/RAF Cancers.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Deciphera Pharmaceuticals Inc revenues increased from $42.1M to $96.1M. Net loss increased 13% to $300M. Revenues reflect U.S. segment increase from $38M to $81.5M, Rest of world segment increase from $1.5M to $5.9M. Higher net loss reflects Research and development - Balancing val increase of 30% to $236.3M (expense), General and administrative - Balancing v increase of 17% to $110.9M (expense).

    Industry: Bio Therapeutic Drugs

    200 Smith St
    WALTHAM
    MASSACHUSETTS 02451-0099
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Gold

    2,004.85 Price
    -1.180% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    BTC/USD

    43,903.65 Price
    -1.630% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    US100

    16,080.90 Price
    +0.500% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    XRP/USD

    0.67 Price
    -0.730% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading